Proinflammatory cytokines in Egyptian elderly with chronic obstructive pulmonary disease

Lung India

Volumn 27, Issue 4, 2010, Pages 225-229

  Amer, Moatassem S ^a   Wahba, Hoda M F ^a   Ashmawi, Samiha S A ^b   Mabrouk, Randa Reda ^b   Sharaf Eldeen, Ahmad A E ^b   Hamza, Sarah A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; cytokines; interleukin 1 beta; tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EGYPT; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PROTEIN BLOOD LEVEL;

EID: 78149389880     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.71956     Document Type: Article

References (25)

1. Agustí AG, Noguera A, Sauleda J, Sals E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60.
2. Barberà JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 2001;164:709-13.
3. Boer WI. Cytokines and therapy in COPD a promising combination? Chest 2002;121:209S-18S.
4. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001;18:50S-9S.
5. Dentener MA, Creutzberg EC, Schols AM, Mantovani A, van't Veer C, Buurman WA, et al, Systemic anti-inflammatory mediators in COPD: Increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax2001;56:7216.
6. Di Vita G, Balistreri CR, Arcoleo F, Buscemi S, Cillari E, Donati M, et al, Systemic inflammatory response in erderly patients following hernioplastical operation. Immun Ageing 2006;3:3.
7. Finder JD, Petrus JL, Hamilton A, Villavicencio RT, Pitt BR, Setbi SM. Signal transduction pathways of IL-1β-mediated iNOS in pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2001;281:L81623.
8. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005;127:558-64.
9. Hodge SJ, Hodge GL, Reynolds PN, Scicchitano R, Holmes M. Increased production of TGF-β and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am J Physiol Lung Cell Mol Physiol 2003;285:L492-9.
10. Joos L, McIntyre L, Ruan J, Connett JE, Anthonisen NR, Weir TD, et al, Association of IL-1β and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokers. Thorax 2001;56:863-6.
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD Guidelines): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2006.
12. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al, C-reactive protein as a cardiovascular risk factor more than an epiphenomenon? Circulation 1999;100:96-102.
13. Lamisse F. Chronic obstructive lung disease. Objective Nutrition. Danone Institute Publications; Jul 2000.
14. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: Data from the Third National Health and Nutrition Examination. Am J Med 2003;114:758-62.
15. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol Regul Integr Comp Physiol1998;274:R577-95.
16. Reuters T. Reuters Health Information. Inflammatory markers predictive of functional ability in COPD patients. Thorax 2006;61:10-28.
17. Gander ML, Fischer JE, Maly FE, von Kdnel R. Effect of the G-308A polymorphism of the tumor necrosis factor (TNF)-α gene promoter site on plasma levels of TNF-α and C-reactive protein in smokers: A crosssectional study. BMC Cardiovasc Disord 2004;4:17.
18. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factorα gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:420-2.
19. Kelly M. Pathophysiology of COPD. Thorax 2002;57:563-4.
20. Senior RM, Griffin GL, Mecham RP. Chemotactic activity of elastinderived peptides. J Clin Invest 1980;66:859-62.
21. Joppa P, Petrasova D, Stancak B. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326-33.
22. Sin DD, Paul Man SF. Are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular morbidity and mortality? Cardiovasc Rev Rep 2004;25:168-70.
23. Soriano JB, Visick GT, Muellerova H. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-107.
24. Weiss ST, DeMeo DL, Postma DS. COPD: Problems in diagnosis and measurement. Eur Respir J 2003;21:4S-12S.
25. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med 2005;26:142-53.